Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
UBS
Fish and Richardson
Covington
Julphar
Cerilliant
US Army
Deloitte
Cantor Fitzgerald

Generated: July 19, 2018

DrugPatentWatch Database Preview

Ani Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for ANI PHARMS INC, and when can generic versions of ANI PHARMS INC drugs launch?

ANI PHARMS INC has one hundred and fifty-five approved drugs.

There is one US patent protecting ANI PHARMS INC drugs.

There are fourteen patent family members on ANI PHARMS INC drugs in eleven countries and thirty-one supplementary protection certificates in nine countries.

Summary for Ani Pharms Inc
International Patents:14
US Patents:1
Tradenames:90
Ingredients:86
NDAs:155

Drugs and US Patents for Ani Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ani Pharms Inc CEFADROXIL cefadroxil/cefadroxil hemihydrate FOR SUSPENSION;ORAL 062698-003 Mar 1, 1989 DISCN No No ➤ Sign Up ➤ Sign Up
Ani Pharms Inc VANCOCIN HYDROCHLORIDE vancomycin hydrochloride INJECTABLE;INJECTION 062476-001 Mar 15, 1984 DISCN No No ➤ Sign Up ➤ Sign Up
Ani Pharms Inc EZETIMIBE AND SIMVASTATIN ezetimibe; simvastatin TABLET;ORAL 201890-004 Apr 26, 2017 AB RX No No ➤ Sign Up ➤ Sign Up
Ani Pharms Inc ACETOHEXAMIDE acetohexamide TABLET;ORAL 070870-001 Feb 9, 1987 DISCN No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Ani Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ani Pharms Inc CASODEX bicalutamide TABLET;ORAL 020498-001 Oct 4, 1995 1,712,251 ➤ Sign Up
Ani Pharms Inc ATACAND HCT candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 021093-003 May 16, 2008 5,721,263 ➤ Sign Up
Ani Pharms Inc ATACAND candesartan cilexetil TABLET;ORAL 020838-001 Jun 4, 1998 5,705,517*PED ➤ Sign Up
Ani Pharms Inc ATACAND HCT candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 021093-001 Sep 5, 2000 5,721,263 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ANI PHARMS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 4 mg, 8 mg, 16 mg and 32 mg ➤ Subscribe 2006-12-22
➤ Subscribe Tablets 32 mg/25 mg ➤ Subscribe 2009-03-06
➤ Subscribe Tablets 16 mg/12.5 mg and 32 mg/12.5 mg ➤ Subscribe 2008-06-25

Non-Orange Book US Patents for Ani Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,040,086 Timed, sustained release systems for propranolol ➤ Sign Up
9,358,214 Timed, sustained release systems for propranolol ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Ani Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
70044 Netherlands ➤ Sign Up PRODUCT NAME: CANDESARTAN, DESGENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF VAN DE 1-(CYCLOHEXYLOXYCARBONYLOXY) ETHYLESTE R, IN HET BIJZONDER CILEXETILI CANDESARTANAS, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: RVG 21703 - RVG 21706 19971013; FIRST REGISTRATION: GB PL 15661/0001 - PL 15661/0004 19970429
C/GB12/058 United Kingdom ➤ Sign Up PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
C0021 Belgium ➤ Sign Up PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
C/GB02/037 United Kingdom ➤ Sign Up PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Mallinckrodt
Cantor Fitzgerald
Cipla
Express Scripts
Johnson and Johnson
Farmers Insurance
Baxter
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.